AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders November 24, 2025
Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials November 3, 2025
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease October 3, 2025
